[HTML][HTML] Management of chronic myeloid leukemia in 2023–common ground and common sense
J Senapati, K Sasaki, GC Issa, JH Lipton… - Blood cancer …, 2023 - nature.com
With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
Management of chronic myeloid leukemia in 2023-common ground and common sense
J Senapati, K Sasaki, GC Issa, JH Lipton… - Blood cancer …, 2023 - pubmed.ncbi.nlm.nih.gov
With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
Management of chronic myeloid leukemia in 2023–common ground and common sense
J Senapati, K Sasaki, GC Issa… - Blood cancer …, 2023 - mdanderson.elsevierpure.com
With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
Management of chronic myeloid leukemia in 2023-common ground and common sense.
J Senapati, K Sasaki, GC Issa, JH Lipton… - Blood Cancer …, 2023 - europepmc.org
With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
[HTML][HTML] Management of chronic myeloid leukemia in 2023–common ground and common sense
J Senapati, K Sasaki, GC Issa, JH Lipton… - Blood Cancer …, 2023 - ncbi.nlm.nih.gov
With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
Management of chronic myeloid leukemia in 2023–common ground and common sense
J Senapati, K Sasaki, GC Issa, JH Lipton… - Blood Cancer …, 2023 - search.proquest.com
With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
Management of chronic myeloid leukemia in 2023–common ground and common sense.
J Senapati, K Sasaki, GC Issa, JH Lipton… - Blood Cancer …, 2023 - search.ebscohost.com
With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
Management of chronic myeloid leukemia in 2023-common ground and common sense.
J Senapati, K Sasaki, GC Issa, JH Lipton… - Blood Cancer …, 2023 - europepmc.org
With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
Management of chronic myeloid leukemia in 2023–common ground and common sense.
J Senapati, K Sasaki, GC Issa, JH Lipton… - Blood Cancer …, 2023 - search.ebscohost.com
With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …